Skip to main content
. 2021 Mar 6;13(5):1135. doi: 10.3390/cancers13051135

Figure 5.

Figure 5

Dinaciclib inhibits Polymerase II (Pol II) C-terminal domain (CTD) Ser2 phosphorylation and concomitantly reduces in Bcl-2 expression. (a) Immunoblots of Pol II and Pol II pSer2 in Ishikawa cells following 4 h and 20 h of treatment with dinaciclib and the vehicle control and (b) the corresponding densitometry data (normalised to Glyceraldehyde-3-phosphate dehydrogenase (GAPDH)). (c) Immunoblots of Pol II and Pol II pSer2 in HEC-1A cells following dinaciclib treatment and (d) the corresponding densitometry data. qPCR data from (e) Ishikawa and (f) HEC-1A samples showing Mcl-1, Bcl-2, and survivin mRNA levels following 40 nM dinaciclib treatment for 24 h. Transcript levels are normalised to the reference gene RPS18 and expressed relative to control samples. Statistical significance was calculated by ANOVA followed by Dunnett’s test. * p value < 0.05, ** p value < 0.01, *** p value < 0.001, **** p value < 0.0001.